Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.

Rodabe N. Amaria,Michael A. Postow,Michael T. Tetzlaff,Merrick I. Ross,Isabella C. Glitza,Jennifer L. McQuade,Michael K. K. Wong,Jeffrey E. Gershenwald,Ryan P. Goepfert,Emily Z. Keung,Sarah B. Fisher,Denái R. Milton,Sapna Pradyuman Patel,Adi Diab,Lauren Simpson,Michael A. Davies,Jennifer A. Wargo,Elizabeth M. Burton,Charlotte E. Ariyan,Hussein Abdul-Hassan Tawbi

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.

2021

9502Background: Neoadjuvant therapy (NT) for pts with clinical stage III melanoma remains an active area of research interest. Recent NT trial data demonstrates that achieving a pathologic complete...

Keywords:

Medicine
Internal medicine
Nivolumab
Neoadjuvant therapy
Oncology
Stage III melanoma
LAG3
Adjuvant
Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations